ZWZhuo Wan

Zhuo Wan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhuo Wan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Chaojun Song

    School of Life Science, Northwestern Polytechnical University, Xi’an, China

    1 shared publication
  • Chenguang Zhou

    Department of Hematology, Tangdu Hospital, No. 569, Xinsi Road, Baqiao District, Xi'an, Shaanxi, China

    1 shared publication
  • Dong Wang

    Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants, Department of Pharmaceutical Chemistry and Analysis, School of Pharmacy, Air Force Medical University, Xi’an 710032, China

    1 shared publication
  • Guoping Ren

    Department of Hematology, Tangdu Hospital, No. 569, Xinsi Road, Baqiao District, Xi'an, Shaanxi, China

    1 shared publication
  • Hua He

    Department of Hematology, Tangdu Hospital, No. 569, Xinsi Road, Baqiao District, Xi'an, Shaanxi, China

    1 shared publication
  • Jiayue Xi

    Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants, Department of Pharmaceutical Chemistry and Analysis, School of Pharmacy, Air Force Medical University, Xi’an 710032, China

    1 shared publication

Latest Publications

  • Open Access

    Application of personalized nursing based on dynamic monitoring of oral pH in oral management of patients with hematological diseases undergoing chemotherapy

    by Xiao Zhang, Guoping Ren, Weiwei Qin, Zhuo Wan, Hua He, Wangbing Xue, Chenguang Zhou, Jizhen Yang

    To investigate the implications of salivary pH for the occurrence of oral mucositis (OM) in patients with hematological diseases during consolidation chemotherapy with high-dose cyclidine, and to evaluate the effect of personalized alkalization care guided by dynamic pH monitoring on the healing of oral ulcers in acidic subgroups. The study was conducted using a two-stage design. The first phase was a prospective cohort observation, which included 100 patients who received high-dose cytiabine (≥ 2 g/m2/ time) consolidation chemotherapy in the hematology department of a hospital from May 2024 to May 2025. They were uniformly given basic oral care and saliva pH and OM grades were recorded daily. OM was determined based on the occurrence of WHO oral mucositis grade ≥ 2 within a 28-day cycle. In the second stage, patients who developed OM in the first stage were selected for persistent acidic microenvironment (pH < 6.0 for ≥ 3 consecutive days), and randomized controlled trials (1:1 area randomization) were conducted to compare ulcer healing time between "pH monitoring guided alkalization care" and "routine care", and to observe pH changes and pain VAS scores on the 3rd and 7th days after intervention. Statistical analysis, in addition to the conventional intergroup comparisons, supplemented multivariate models were used to adjust for outcomes (Logistic regression in the first stage, Cox regression or generalized linear model in the second stage), and effect sizes and 95% confidence intervals were reported. In the first stage, there were 53 cases of OM occurrence and 47 cases of no OM occurrence. The baseline pH difference was not statistically significant (6.32 ± 0.42 vs. 6.17 ± 0.39, P = 0.067). In the second stage, a total of 34 cases were included in the acidic subgroup, 20 in the intervention group, and 14 in the conventional group; The ulcer healing time in the intervention group was shorter than that in the conventional group (6.8 ± 1.2 d vs. 11.3 ± 2.1 d, P < 0.001), and the pH on the third day after intervention was higher than that in the conventional group (6.55 ± 0.15 vs. 6.09 ± 0.19, P < 0.001). A single baseline pH is difficult to serve as a universal early warning indicator for OM occurrence; In the persistent acidic microenvironment subgroup, personalized alkalization care guided by dynamic pH monitoring can accelerate the return of the oral microenvironment to neutrality and shorten the ulcer healing cycle.

  • Open Access

    Rational Combination of Dominant and Subdominant Antigens with Nanoadjuvant Elicits Durable Immunity Against Staphylococcus aureus

    by Zhuoyue Shi, Jiayue Xi, Minxuan Cui, Zhuo Wan, Yufei Hou, Zhengjun Ma, Nan Sun, Yupu Zhu, Muqiong Li, Dong Wang, et al.

    Objectives: In response to the challenge that Staphylococcus aureus (S. aureus) vaccines fail to induce durable protective immunity, this study aims to develop a novel antigen-adjuvant co-design strategy. Specifically, we rationally combined the immunodominant toxin antigen LukS-PV with the immunologically subdominant adhesin antigen ClfA, co-delivered via the PLGA-PEG nanoadjuvant system, to elicit synergistic, durable, and balanced humoral and cellular immune responses. Methods: Firstly, recombinant antigens LukS-PV and ClfA were individually covalently conjugated to PLGA-PEG 25% nanoparticles (25% NPs) using EDC/NHS chemical coupling to construct a combined nanovaccine, followed by systemic safety verification in a mouse model. Subsequently, specific antibody titers were detected by ELISA, and the secretion levels of IL-4, IFN-γ, and IL-17A were measured by ELISPOT assay to comprehensively evaluate the humoral and cellular immune responses induced by the vaccine. Finally, the protective efficacy of the vaccine was assessed through acute and long-term (up to 180 days) lethal challenge experiments, thereby verifying the effectiveness of this co-design strategy based on rational antigen selection. Results: The combined vaccine group (25% NPs-rClfA + 25% NPs-rLukS-PV) not only elicited high levels of specific antibodies but, more importantly, induced robust cellular immune responses dominated by Th1 and Th17 cells. Challenge experiments confirmed that the protective efficacy of the combined vaccine was significantly superior to that of any single-antigen vaccine and provided complete protection for up to 180 days. Crucially, the same antigen combination formulated with a traditional aluminum adjuvant failed to confer this durable protection, underscoring the essential role of adjuvant synergy. Conclusions: This study demonstrates that rational combination of immunodominant and subdominant antigens with a compatible nanoadjuvant induces synergistic and durable immunity against S. aureus. This co-design strategy addresses key limitations of previous vaccines and provides a promising foundation for future clinical development.